Stefen A Boehme

Summary

Publications

  1. ncbi A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation
    Stefen A Boehme
    Actimis Pharmaceuticals, Inc, 10835 Road to the Cure, San Diego, CA 92121, USA
    Int Immunol 21:81-93. 2009
  2. ncbi Antagonism of CRTH2 ameliorates chronic epicutaneous sensitization-induced inflammation by multiple mechanisms
    Stefen A Boehme
    Actimis Pharmaceuticals, Inc, 10835 Road to the Cure, San Diego, CA 92121, USA
    Int Immunol 21:1-17. 2009
  3. ncbi Murine bone marrow-derived mast cells express chemoattractant receptor-homologous molecule expressed on T-helper class 2 cells (CRTh2)
    Stefen A Boehme
    Actimis Pharmaceuticals, Inc, 10835 Road to the Cure, San Diego, CA 92121, USA
    Int Immunol 21:621-32. 2009
  4. ncbi Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide
    David G Alleva
    Neurocrine Biosciences, Inc, 10555 Science Center Drive, San Diego, CA 92121 1102, USA
    Diabetes 51:2126-34. 2002
  5. ncbi Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma
    David G Alleva
    Neurocrine Biosciences, Inc, San Diego, California, USA
    J Leukoc Biol 71:677-85. 2002
  6. ncbi Cutting edge: serotonin is a chemotactic factor for eosinophils and functions additively with eotaxin
    Stefen A Boehme
    La Jolla Institute for Molecular Medicine, San Diego, CA 92121, USA
    J Immunol 173:3599-603. 2004

Collaborators

  • Yuko Kawakami
  • Savita P Rao
  • David G Alleva
  • Paul D Crowe
  • Eric B Johnson
  • Paul J Conlon
  • Francisco M Lio
  • Peter A Gottlieb
  • Nicholas Ling
  • Anil Pahuja
  • Theresa Motheral
  • Dale Wegmann
  • Liping Jin
  • Amitabh Gaur
  • Amy Putnam

Detail Information

Publications6

  1. ncbi A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation
    Stefen A Boehme
    Actimis Pharmaceuticals, Inc, 10835 Road to the Cure, San Diego, CA 92121, USA
    Int Immunol 21:81-93. 2009
    ..This suggests that CRTH2 antagonism may be a viable route for therapeutic intervention in allergic skin diseases, such as atopic dermatitis...
  2. ncbi Antagonism of CRTH2 ameliorates chronic epicutaneous sensitization-induced inflammation by multiple mechanisms
    Stefen A Boehme
    Actimis Pharmaceuticals, Inc, 10835 Road to the Cure, San Diego, CA 92121, USA
    Int Immunol 21:1-17. 2009
    ..Collectively, these findings suggest that CRTH2 has a pivotal role in mediating the inflammation and the underlying immune response following epicutaneous sensitization...
  3. ncbi Murine bone marrow-derived mast cells express chemoattractant receptor-homologous molecule expressed on T-helper class 2 cells (CRTh2)
    Stefen A Boehme
    Actimis Pharmaceuticals, Inc, 10835 Road to the Cure, San Diego, CA 92121, USA
    Int Immunol 21:621-32. 2009
    ..Both these processes were inhibited by the CRT(h)2 antagonist. These results raise the possibility that the functional consequences of the PGD(2)-CRT(h)2 interaction on mast cells may be relevant in allergic inflammation...
  4. ncbi Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide
    David G Alleva
    Neurocrine Biosciences, Inc, 10555 Science Center Drive, San Diego, CA 92121 1102, USA
    Diabetes 51:2126-34. 2002
    ..This study is the first to report therapeutic activity of an APL derived from an islet beta-cell-specific antigen in type 1 diabetes...
  5. ncbi Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma
    David G Alleva
    Neurocrine Biosciences, Inc, San Diego, California, USA
    J Leukoc Biol 71:677-85. 2002
    ..These results suggest that drugs such as thiazolidinediones may be most effective in suppressing Mphi activity early (i.e., in the absence of lymphocyte-derived IFN-gamma) in the inflammatory process...
  6. ncbi Cutting edge: serotonin is a chemotactic factor for eosinophils and functions additively with eotaxin
    Stefen A Boehme
    La Jolla Institute for Molecular Medicine, San Diego, CA 92121, USA
    J Immunol 173:3599-603. 2004
    ..These results suggest that 5-HT is a potent eosinophil-active chemoattractant that can function additively with eotaxin and a dual CCR3/5-HT2A receptor antagonist may be more effective in blocking allergen-induced eosinophil recruitment...